Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...

Coagulation

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Safety and efficacy of a new academic CD19-directed CAR-T cell for refractory/relapsed non-Hodgkin lymphoma and acute lymphoblastic leukemia in Brazil.

Bone marrow transplantation·2024

Same author

Age-related Morphofunctional Changes in Sickle Cell Mice Bone Marrow Mesenchymal Stromal Cells.

Hematology/oncology and stem cell therapy·2024

Same author

DENV-1 genotype V circulation during the nonepidemic period in the Northeast of São Paulo State endemic area.

Journal of medical virology·2024

Same author

Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and Adults.

The New England journal of medicine·2024

Same author

Chimeric antigen-receptor (CAR) engineered natural killer cells in a chronic myeloid leukemia (CML) blast crisis model.

Frontiers in immunology·2024

Same author

Time-dependent vaccine efficacy estimation quantified by a mathematical model.

PloS one·2023

Search research articles

Related Experiment Video

Updated: Feb 22, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Purification and Autoactivation Method for Recombinant Coagulation Factor VII.

Vladimir Granovski¹, Marcela C C Freitas^2,3, Mario Soares Abreu-Neto³

¹Center for Cell-based Therapy CTC, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil. granovski.v@gmail.com.

Methods in Molecular Biology (Clifton, N.J.)

|September 19, 2017

Summary

This summary is machine-generated.

Recombinant coagulation factor VII (rFVII) purification is simplified using affinity resin and dialysis. This fast, scalable method aids in processing rFVII for hemophilia treatment.

Keywords:

Affinity chromatography FVII autoactivation Recombinant coagulation factor VII rFVII purification methodology

More Related Videos

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis

Published on: December 29, 2023

Detection and Removal of Nuclease Contamination During Purification of Recombinant Prototype Foamy Virus Integrase

Detection and Removal of Nuclease Contamination During Purification of Recombinant Prototype Foamy Virus Integrase

Published on: December 8, 2017

Related Experiment Videos

Last Updated: Feb 22, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis

Published on: December 29, 2023

Detection and Removal of Nuclease Contamination During Purification of Recombinant Prototype Foamy Virus Integrase

Detection and Removal of Nuclease Contamination During Purification of Recombinant Prototype Foamy Virus Integrase

Published on: December 8, 2017

Area of Science:

Biochemistry
Protein Purification
Hemophilia Treatment

Background:

Recombinant coagulation factor VII (rFVII) is crucial for treating hemophilia A/B patients with inhibitors to FVIII and FIX.
rFVII is a 50 kDa glycosylated zymogen that becomes active after cleavage, with a short plasma half-life.
Efficient and rapid processing of rFVII is essential for its therapeutic application, including freeze-drying.

Purpose of the Study:

To develop a simple, fast, and scalable purification process for recombinant coagulation factor VII.
To optimize the purification of rFVII for clinical use.

Main Methods:

Utilized affinity FVII Select resin for rFVII purification.
Employed a dialysis system as part of the purification sequence.
Focused on a simplified and rapid purification strategy.

Main Results:

A straightforward and rapid purification sequence for rFVII was established.
The described method is amenable to large-scale production.
The purification process is efficient for preparing rFVII.

Conclusions:

The developed purification method using FVII Select resin and dialysis is simple, fast, and scalable.
This approach facilitates the efficient processing of rFVII for hemophilia treatment.
The method offers a practical solution for producing therapeutic rFVII.